ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1891

Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients

Rutvin Kyada1, Jean Liew2, Maureen Dubreuil3, Matthew Brown4, Mariko Ishimori5, John Reveille6, Michael Ward7, Michael Weisman8 and Lianne S Gensler9, 1Boston University, Boston, MA, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3Section of Rheumatology, Boston University School of Medicine, Boston, MA, 4King's College London, London, United Kingdom, 5Cedars-Sinai Health System, Los Angeles, CA, 6UTHealth Houston Division of Rheumatology, Houston, 7NIH, Bethesda, MD, 8Stanford University, Los Angeles, CA, 9Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Meeting: ACR Convergence 2024

Keywords: Ankylosing spondylitis (AS), Epidemiology, exercise, obesity, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Pain remains a common symptom of axial spondyloarthritis (axSpA) despite availability of effective therapies. Physical activity may benefit pain and is guideline recommended but remains underutilized, while chronic opioid use remains high. Whether higher physical activity can reduce opioid use in people living with axSpA is unknown. We assessed the association of physical activity levels with chronic opioid use in a prospective radiographic axSpA (r-axSpA) cohort.

Methods: We longitudinally analyzed adults with r-axSpA in the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS) cohort followed across 2003-2018. Clinical information, including physical activity and medication use, was collected every 6 months. The outcome, chronic opioid use, was defined as any daily opioid use for ≥3 months prior to the visit, and secondarily defined using thresholds of ≥4 months, ≥6 months, or any use. The exposure was dichotomized moderate/high versus low physical activity level, based on cumulative metabolic equivalents of task-minutes per week calculated from patient-reported physical activity based on modified International Physical Activity Questionnaire thresholds. We excluded patients with baseline chronic opioid use.

Time-varying confounders (e.g. disease activity) may be affected by the exposure of interest (treatment-confounder feedback), which is difficult to account for using standard methods. Thus, we estimated the effect of time-varying physical activity on chronic opioid use by accounting for baseline (demographics, site, symptom duration, comorbidities, study entry year) and time-dependent confounders (disease activity, physical function, medication use) using marginal structural models (MSM). We used inverse probability weighting to account for time-dependent confounders. In sensitivity analyses, we conducted time-varying Cox proportional hazards models with adjustment for the same confounders. We used multiple imputation with chained equations for missingness at the study visit level (physical activity level, comorbidities, symptom duration, disease activity, physical function, and medication use).

Results: We included 788 patients (median age 41 years, 74% male, 81% white). The low physical activity group (n=439, 56%) had higher disease activity levels and comorbidity prevalence (Table 1). In the main analysis using MSM, moderate/high physical activity had a 28% lower risk of chronic opioid use, although this was not statistically significant (HR 0.72, 95% CI 0.43-1.01) (Figure 1). For secondary outcome definitions, the magnitude of effect was attenuated in MSM models. Cox models did not demonstrate an association between physical activity levels and chronic opioid use (HR 0.98, 95% CI 0.85-1.14 for the primary outcome).

Conclusion: In this prospective r-axSpA cohort, longitudinal analyses accounting for time-varying exposures and treatment-confounder feedback suggest a possible protective effect of higher physical activity on incident chronic opioid use, although results were not statistically significant.

Supporting image 1

Table 1: Baseline descriptive characteristics of the included cohort and stratified by physical activity level

Supporting image 2

Figure 1: Results from multivariable analyses for the longitudinal association of physical activity levels with chronic opioid use.

Abbreviations: aHR: adjusted hazard ratio; MSM: marginal structural model
Cox model adjusts for baseline age, sex, race, ethnicity, site, symptom duration, coronary artery disease, depression, diabetes, BASFI, BASDAI, and the use of TNF inhibitors, NSAIDs, and steroids


Disclosures: R. Kyada: None; J. Liew: None; M. Dubreuil: Amgen, 2, Pfizer, 5, UCB Pharma, 2; M. Brown: None; M. Ishimori: None; J. Reveille: None; M. Ward: None; M. Weisman: None; L. Gensler: AbbVie/Abbott, 2, Acelyrin, 2, Eli Lilly, 2, Fresenius Kabi, 2, Janssen, 2, MoonLake, 2, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Kyada R, Liew J, Dubreuil M, Brown M, Ishimori M, Reveille J, Ward M, Weisman M, Gensler L. Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/association-of-physical-activity-levels-on-chronic-opioid-use-in-radiographic-axial-spondylitis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-physical-activity-levels-on-chronic-opioid-use-in-radiographic-axial-spondylitis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology